This $520-Million Pot Stock Is Now Too Cheap to Ignore

Discover how HEXO Corp (TSX:HEXO)(NYSE:HEXO) is primed to become the next big thing in cannabis investing.

| More on:
Modern buildings in business district

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s premium investing services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn more

Demand for legal pot continues to climb to new heights. Investment bank Cowen Inc has raised its 2030 sales forecast from $75 billion to $80 billion, only to bump it again to $85 billion last November.

Globally, several analysts are now expecting sales to peak above $200 billion. If adjacent markets are any indication, even these rosy estimates could prove overly conservative.

Global alcohol sales surpass $1.4 trillion, while annual cigarette sales are above $900 billion. It wouldn’t be a huge surprise to see cannabis demand ultimately reach these levels.

Despite optimism for demand, the 2019 pot bear market crushed nearly every cannabis stock. Marijuana exchange-traded funds (ETFs) have been cut in half since their summer highs.

These opposing dynamics have created a once-in-a-lifetime opportunity for both growth and value investors.

The following stock, now valued at just $520 million, is expected to triple sales over the next 12 months. Due to its relatively small size, however, the market has assigned this company a bargain valuation. This stock is simply too cheap to ignore.

Play the game right

Now that the cannabis market has matured, we can get a grasp on how investors are able to take advantage.

Some companies are focused purely on growing cannabis. These stocks are best avoided. As with any other commodity, pricing pressures will surely come.

Last summer, for example, Tilray stock slumped after pricing fell by more than 20%. Over the following weeks, the industry sank as pricing fears mounted. Companies that only produce commoditized pot face a difficult future.

Other companies are growing pot and creating value-add products to woo consumers. Ideally, these firms want to create trusted brands that instill customer loyalty — a strategy straight out of Coca-Cola Co‘s playbook. If you can create brand loyalty, you can maintain industry-leading margins for decades to come.

Unfortunately, creating a beloved brand from scratch is difficult. It’s why Coca-Cola has been the number one global soda for our entire lives. Owning a leading brand is one thing, but inventing one is a completely different ballgame.

One pot company realized a shortcut to the equation. Rather than building its own brands, it’s leveraging the loyal fan bases of existing brands. This strategy, above all others, has the potential to create billions in shareholder value.

This is your best bet

HEXO Corp (TSX:HEXO)(NYSE:HEXO) is building the first cannabis platform. Instead of building everything itself, it’s simply providing the basic infrastructure, trusting other companies to launch brands that pot consumers love.

THC-infused beverages, for example, hold the potential to double or triple global cannabis demand. Rather than creating a beverage brand out of thin air, Hexo partnered with Molson Coors Canada Inc. (TSX:TPX.B)(NYSE:TAP) to co-create pot-based drinks. This month, their first products should hit the shelves.

It’s a good bet that Molson-branded products will outsell competition from unknown brands. I’m also willing to bet that pot-based cosmetics from Estee Lauder and cannabis medicines from Johnson & Johnson would best any pot-specific brand.

This is exactly what Hexo is banking on. This year, it wants to forge additional partners across new categories such as edibles, sleep aids, cosmetics, and more.

Hexo’s strategy is under-appreciated, especially given that its market cap is only hovering around $500 million. As these partnership deals gain traction, it has a shot at becoming one of the most valuable pot stocks on the market.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

The Motley Fool recommends HEXO., HEXO., and Johnson & Johnson. Fool contributor Ryan Vanzo has no position in any stocks mentioned. 

More on Cannabis Stocks

Cannabis smoke
Cannabis Stocks

Canopy Growth Stock: Is Now a Good Time to Invest?

The road ahead is highly uncertain for Canopy Growth, as the stock is plagued with losses and seemingly unsurmountable industry…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

TLRY Stock: Should You Invest Now?

TLRY is a Canadian cannabis stock which is trading 91% below record highs. Let's see if you should own TLRY…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Is Tilray Stock a Buy in February 2023?

Despite the volatile cannabis sector, Tilray could be a superb buy for long-term investors.

Read more »

Young woman sat at laptop by a window
Cannabis Stocks

Is SNDL Stock a Buy in February 2023?

SNDL is a beaten-down cannabis stock. While its revenue growth is exceptional, a weak balance sheet has driven stock prices…

Read more »

A cannabis plant grows.
Cannabis Stocks

TLRY Stock: Here’s What’s Coming in 2023

Tilray Inc. (TSX:TLRY) is geared up for big growth this decade and looks like one of the top cannabis stocks…

Read more »

A person holds a small glass jar of marijuana.
Cannabis Stocks

Canopy Growth Stock: Here’s What’s Coming in 2023

Canopy Growth stock has made a lot of new moves in the last few months, but where is the company…

Read more »

A cannabis plant grows.
Cannabis Stocks

Better Cannabis Buy: Canopy Growth Stock or Tilray?

Only two TSX weed stocks can deliver substantial returns in the highly anticipated growth of the global cannabis market.

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Is Tilray Stock a Buy in January 2023?

Tilray stock has lost 50% of its value in the last 12 months, in line with its peers.

Read more »